Table 1.
Baseline demographic and clinical characteristics
| BI 655064 (n=44) | Placebo (n=23) | |
| Age, years | 53.7±13.3 | 55.1±8.3 |
| Female, n (%) | 37 (84.1) | 18 (78.3) |
| BMI | 26.06±4.57 | 31.09±5.67 |
| Region, n (%) | ||
| Eastern Europe | 28 (63.6) | 15 (65.2) |
| Western Europe | 16 (36.4) | 8 (34.8) |
| Ethnicity, n (%) | ||
| White | 43 (97.7) | 23 (100) |
| Asian | 1 (2.3) | 0 |
| Disease duration, years | 8.3±7.5 | 5.8±4.7 |
| Anti-TNFα naive, n (%) | 38 (86.4) | 23 (100) |
| DAS28-CRP | 5.39±0.85 | 5.53±0.79 |
| DAS28-ESR | 6.21±0.73 | 6.16±0.80 |
| CRP, mg/L | 9.80±12.63 | 23.61±26.46 |
| ESR, mm/hour | 37.45±18.67 | 44.45±23.76 |
| Duration of morning stiffness, mins | 84.1±61.6 | 67.3±53.1 |
| SJC 66 | 14.38±7.41 | 12.86±6.94 |
| TJC 68 | 21.25±11.87 | 19.77±10.84 |
Except where indicated otherwise, values are mean±SD.
BMI, body mass index; CRP, C-reactive protein;DAS28, Disease Activity Score in 28 joints;ESR, erythrocyte sedimentation rate; SD, standard deviation; SJS 66, swollen joint count based on 66 joints; TJC 68, tender joint count based on 68 joints; TNFα, tumour necrosis factor α.